ARA-290 / Cibinetide: clinical study of small-fiber neuropathy

This Research Library page summarizes independently published research on Cibinetide / ARA-290. For each study, the research model, key finding, and main limitation are stated.

Study 1

Level of evidence: Human research - placebo-controlled

Topic: Neuropathic symptoms and small nerve fibers.

Key finding: Improvements in some patient-reported outcomes and an increase in corneal nerve fiber density were reported.

Main limitation: Small study group and short duration.

Source: Original publication via PubMed

Study 2

Level of evidence: Human research - phase 2b

Topic: Nerve fiber abundance, pain, and functioning.

Key finding: An increase in small nerve fiber measures was reported; relationships with clinical outcomes were exploratory.

Main limitation: Surrogate endpoints and short treatment duration.

Source: Original publication via PubMed

Study 3

Level of evidence: Human research

Topic: Metabolic control and neuropathic symptoms in type 2 diabetes.

Key finding: The researchers reported signals of improvement in some metabolic and neuropathic outcomes.

Main limitation: Early clinical development; confirmation in larger independent trials is needed.

Source: Original publication via PubMed

Scientific scope: Research on a molecule, research model, or pharmaceutical formulation does not constitute evidence of the efficacy, safety, purity, or suitability of a commercial Peptidera product. This page does not provide treatment or usage advice.

Header image: illustrative visualization, not a research result.